Cirmtuzumab for Metastatic Castration-resistant Prostate Cancer

Phase-Based Progress Estimates
Metastatic Castration-resistant Prostate CancerCirmtuzumab - Drug
What conditions do you have?

Study Summary

This trial is testing if cirmtuzumab, a drug that targets a protein involved in cancer growth, can help treat men with metastatic prostate cancer that has resisted other treatments.

Eligible Conditions
  • Metastatic Castration-resistant Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: Patients will be followed from study entry to death or date last known alive, assessed up to 36 months

Month 36
Composite clinical benefit
Incidence of treatment-emergent adverse events
Overall survival
Radiographic progression free survival
Recommended phase 2 dose of docetaxel combined with cirmtuzumab
Safety and tolerability
Time to PSA progression
Time to first subsequent anti-cancer therapy
Time to first symptomatic skeletal event
Time to increase in the total alkaline phosphatase level
Total alkaline phosphatase response

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Cirmtuzumab + Docetaxel
1 of 1

Experimental Treatment

32 Total Participants · 1 Treatment Group

Primary Treatment: Cirmtuzumab · No Placebo Group · Phase 1

Cirmtuzumab + Docetaxel
Experimental Group · 1 Intervention: Cirmtuzumab · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: patients will be followed from study entry to death or date last known alive, assessed up to 36 months

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,028 Previous Clinical Trials
1,805,989 Total Patients Enrolled
Rana McKayStudy ChairUCSD

Eligibility Criteria

Age 18+ · Male Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients with histologically or cytologically confirmed adenocarcinoma of the prostate.
You have progressive disease.
You have a performance status of ≤1 (Karnofsky ≥80%).
You have castrate levels of serum testosterone < 50 ng/dL.